Allison DeAngelis
STAT
Mountain View, CA, United States
Contact Allison
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Allison:
SVB, biotech’s bank of choice, just failed. It could have ripple effects
Silicon Valley Bank, which does business with roughly half of the nation’s tech and biotech companies, failed on Friday. Now biotech startups are left wondering: Who’s going to finance the industry? → Read More
CRISPR patent fight redux? A new battle is brewing among biotechs over next-gen gene-editing tools
The next CRISPR gene-editing patent war might look quite different; it's shaping up to be a free-for-all among a multitude of companies and labs. → Read More
Pfizer scraps half of participants in Lyme disease drug trial due to quality issues
Pfizer and partner Valneva's trial for a Lyme disease vaccine candidate hit a snag due to quality issues with a third-party trial operator. → Read More
CRISPR pioneer Feng Zhang launches new genetic delivery startup with $193 million
The startup's technology has the potential to address significant limitations with gene editing treatments and mRNA therapies. → Read More
With $520 million in hand, two entrepreneurs try to upend the biotech funding model
With $520 million in hand, two entrepreneurs are trying to upend the biotech funding model with Curie.Bio. → Read More
In another pharma shakeup, Sanofi loses top executive known for overhauling R&D
Sanofi head of R&D John Reed is leaving the pharmaceutical giant to pursue a new opportunity, the company announced Monday. → Read More
KKR veteran sets records with $3.9 billion health care fund
The former head of health care investing at private equity giant KKR has set records with the first fundraising for his new firm. → Read More
Focused exclusively on life sciences, three top investors set out on their own
Dimension, a new VC focused exclusively on the life sciences, was launched by veterans of Lux Capital and Obvious Ventures. → Read More
How one private biotech seized on JPM to emerge from stealth and tell its story
Out of stealth, Rezo Therapeutics seized on #JPM23 to tell its story. → Read More
Biotech startups are hungry for dollars. Here’s what one pharma executive was looking for at JPM
The balance of power between biotech startups and big pharma has shifted — but Bayer executive Marianne De Backer is still looking for deals. → Read More
A flurry of pharma acquisitions kick off JPM week after a slow year for deals
Four life science companies have announced acquisitions worth roughly $4.5 billion in total, raising hopes that 2023 will yield more M&A. → Read More
Money troubles and M&A: What's on biotech insiders' minds ahead of a not-so-celebratory JPM week
Nearly 70% of biotech insiders say financing — such as raising venture capital or launching an IPO — will be a challenge in 2023. → Read More
Biogen shakes up R&D chief role, makes Singhal permanent replacement
More than a year after Al Sandrock was pushed out as Biogen’s R&D chief, the company has set permanent plans to replace him into motion. → Read More
Roivant-Pfizer inflammatory bowel drug hits high expectations in mid-stage study
In a Phase 2 study, a Roivant-Pfizer drug helped 32% of patients with ulcerative colitis go into remission, compared to 12% in the placebo group. → Read More
Former MIT professor tried to influence investigation of harassment at lab, report states
A full copy of the report, leaked Wednesday, details complaints against Sabatini and said he tried to influence what members of his lab told investigators. → Read More
Young private equity firm Catalio to absorb hedge fund HealthCor, capping off busy year of investment M&A
The HealthCor acquisition will transform Catalio Capital into a one-stop shop for health care investing. → Read More
Listen: Leaky health data, ASH22, & what it takes to get booed by your peers
Why do billionaires get booed? How does Facebook end up with sensitive health data? And does biotech have a dribbling problem? All that and more on the latest episode of "The Readout LOUD" #podcast. → Read More
The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing
Who gets dibs on in-demand medicines? Can you get a refund on an $8 billion buy? And what happens when sweetheart deals go bad? All that and more on "The Readout LOUD" this week. → Read More
'This is not a cure': Consensus begins to emerge on new Alzheimer’s drug
Eisai CEO Ivan Cheung and Jason Karlawish of the Penn Memory Center discussed balancing the potential risks and benefits of lecanemab at a STAT event. → Read More
Listen: Whither PhRMA, Alzheimer’s treatment data revealed, and the first fecal microbiome drug approval
A big Alzheimer's treatment data reveal. The first FDA-approved fecal microbiome drug. And a stinging defeat for Big Pharma's lobbying arm. We cover all that and more on this week's episode of “The Readout LOUD” #podcast. → Read More